Merck KGaA
Merck KGaA Updates Clinical Trial Plans for Several Precision Oncology Candidates
The Darmstadt, Germany-based drugmaker outlined its strategy for advancing an ATR inhibitor, a PARP inhibitor, and an antibody-drug conjugate.
Biocartis, Merck KGaA Extend RAS Testing Partnership to Middle East, North Africa
The companies hope to improve access to biomarker testing to direct more personalized treatment for cancer patients in the region.
Nucleai Raises $14M in Funding Round Led by Merck KGaA's M Ventures
The company said it will use the funds to further apply its AI algorithms in the prospective enrollment of patients in clinical trials.
FDA Grants Full Approval to Merck KGaA's Tepmetko in Advanced METex14-Altered NSCLC
The drug garnered accelerated approval from the FDA in 2021, but the agency has now granted full approval based on additional data.
Merck KGaA Licenses Inspirna's Ompenaclid Outside of the US
The firms also agreed to collaborate on development and commercialization of SLC6A8-targeting follow-on compounds.